Congreso Europeo-Prevenci n 2011

1. 1 1

6. The pooled results of 7 ACE inhibitor trials in 88 860 patients demonstrated a significant reduction in all-cause death of 6% (HR, 0.94 (0.90-0.98), P=0.007). Significant heterogeneity was found with respect to mortality reduction with different ACE inhibitors (P for heterogeneity <0.001, I² 99%). Perindopril-based regimens (investigated in ASCOT, ADVANCE and HYVET) were associated with a statistically significant reduction in all-cause mortality (HR, 0.87; 95% CI, 0.81 to 0.94, P<0.0001), whereas the remaining ACE inhibitors were not.The pooled results of 7 ACE inhibitor trials in 88 860 patients demonstrated a significant reduction in all-cause death of 6% (HR, 0.94 (0.90-0.98), P=0.007). Significant heterogeneity was found with respect to mortality reduction with different ACE inhibitors (P for heterogeneity <0.001, I² 99%). Perindopril-based regimens (investigated in ASCOT, ADVANCE and HYVET) were associated with a statistically significant reduction in all-cause mortality (HR, 0.87; 95% CI, 0.81 to 0.94, P<0.0001), whereas the remaining ACE inhibitors were not.

7. Devices in Hypertension. BP changes with renal sympathetic denervation in refractory HT

14. Dislipidemia. CETP inhibition Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the transfer of CE from HDL to apoB-containing lipoproteins (VLDL and LDL-C)in exchange for triglycerides that are transferred in the reverse direction. CETP inhibitors increase HDL-C and some also lower LDL-C, and therefore have the potential to reduce coronary events. HDL picks up free cholesterol (FC) from extrahepatic tissues. HDL FC is subsequently esterified by LCAT to form cholesteryl esters (CE) The HDL CE may then be delivered to the liver by either of two pathways: 1. A direct pathway following binding of HDL to hepatic SR-B1 2. An indirect pathway involving the CETP-mediated transfer of CE from HDL to VLDL and LDL with subsequent delivery to the liver following binding of LDL to the LDL receptor." After click: Inhibition of CETP prevents the transfer of CE from HDL to the VLDL/LDLfractions and results in an increase in concentration of HDL-C and adecrease in the cholesterol content of the VLDL/LDL. Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the transfer of CE from HDL to apoB-containing lipoproteins (VLDL and LDL-C)in exchange for triglycerides that are transferred in the reverse direction. CETP inhibitors increase HDL-C and some also lower LDL-C, and therefore have the potential to reduce coronary events. HDL picks up free cholesterol (FC) from extrahepatic tissues. HDL FC is subsequently esterified by LCAT to form cholesteryl esters (CE) The HDL CE may then be delivered to the liver by either of two pathways: 1. A direct pathway following binding of HDL to hepatic SR-B1 2. An indirect pathway involving the CETP-mediated transfer of CE from HDL to VLDL and LDL with subsequent delivery to the liver following binding of LDL to the LDL receptor." After click: Inhibition of CETP prevents the transfer of CE from HDL to the VLDL/LDLfractions and results in an increase in concentration of HDL-C and adecrease in the cholesterol content of the VLDL/LDL.

19. PURE study: Substantial underutilization of proven treatments for secondary prevention Use of secondary prevention medications (%) for CVD in 153 996 adults (628 communities from 17 high, middle and low income countries) Results of the Prospective Urban Rural Epidemiologic (PURE) study have been presented by Professor Salim YUSUF (Canada) at the Hot Line I of the ESC Congress, Paris 2011. Aim: to document the rates of use of proven secondary prevention medications in the community in high, mid and low income countries Design: the study enrolled 153 996 adults (aged between 35 and 70 years) from 628 urban and rural communities in 17 countries. Of study population 5650 individuals (%) reported coronary events (in average 5 years ago) and 2292 (%) reported cerebrovascular events (4 years ago), 22 568 (14.7%) were hypertensive and (5%) had diabetes. Study follow up 2003-2010. Countries were classified according to the World Bank classifications at the beginning of the study (2003-2007): High income: Canada, Sweden & UAE Upper middle income: Argentina, Brazil, Poland, Turkey, South Africa, Malaysia Lower middle income: Colombia, Iran, China Low income country: India, Bangladesh, Pakistan, Zimbabwe Results of the Prospective Urban Rural Epidemiologic (PURE) study have been presented by Professor Salim YUSUF (Canada) at the Hot Line I of the ESC Congress, Paris 2011. Aim: to document the rates of use of proven secondary prevention medications in the community in high, mid and low income countries Design: the study enrolled 153 996 adults (aged between 35 and 70 years) from 628 urban and rural communities in 17 countries. Of study population 5650 individuals (%) reported coronary events (in average 5 years ago) and 2292 (%) reported cerebrovascular events (4 years ago), 22 568 (14.7%) were hypertensive and (5%) had diabetes. Study follow up 2003-2010. Countries were classified according to the World Bank classifications at the beginning of the study (2003-2007): High income: Canada, Sweden & UAE Upper middle income: Argentina, Brazil, Poland, Turkey, South Africa, Malaysia Lower middle income: Colombia, Iran, China Low income country: India, Bangladesh, Pakistan, Zimbabwe